These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33796513)

  • 1. Treating Choroidal Metastases and Improving Vision with Osimertinib in EGFR T790M-Mutated Lung Adenocarcinoma: A Case Report and Review of the Literature.
    Keshwani K; Roelofs KA; Hay G; Lewis R; Plowman N
    Ocul Oncol Pathol; 2021 Mar; 7(1):26-30. PubMed ID: 33796513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.
    Wu L; Zhong W; Li A; Qiu Z; Xie R; Shi H; Lu S
    Ann Transl Med; 2021 Jun; 9(11):950. PubMed ID: 34350265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer.
    Field MG; Boldt HC; Abu Hejleh T; Binkley EM
    Am J Ophthalmol Case Rep; 2022 Jun; 26():101459. PubMed ID: 35265776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
    Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
    Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.
    Bouchez C; Pluvy J; Soussi G; Nguenang M; Brosseau S; Tourne M; Collin M; Théou-Anton N; Guyard A; Ammar J; Khalil A; Zalcman G; Gounant V
    BMC Cancer; 2020 Dec; 20(1):1186. PubMed ID: 33272243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib administration via nasogastric tube in an EGFR-T790M-positive patient with leptomeningeal metastases.
    Takeda T; Itano H; Takeuchi M; Nishimi Y; Saitoh M; Takeda S
    Respirol Case Rep; 2017 Jul; 5(4):e00241. PubMed ID: 28469919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.
    Uemura T; Oguri T; Okayama M; Furuta H; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Mol Clin Oncol; 2017 Apr; 6(4):525-528. PubMed ID: 28413660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report.
    Li J; Liu X; Yuan C
    Mol Clin Oncol; 2018 Sep; 9(3):321-324. PubMed ID: 30112177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine Kinase Inhibitors in the Treatment of Choroidal Metastases from Non-Small-Cell Lung Cancer: A Case Report and Review of Literature.
    Nair AG; Asnani HT; Mehta VC; Mehta SV; Pathak RS; Palkar AH; Gopinathan I
    Ocul Oncol Pathol; 2017 Jan; 3(1):28-33. PubMed ID: 28275600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary resistance to osimertinib despite acquired
    Chang LK; Chang YL; Shih JY
    Respirol Case Rep; 2020 Mar; 8(2):e00532. PubMed ID: 32042433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo
    Sumi T; Kamada K; Shijubou N; Yamada Y; Nakata H; Mori Y; Chiba H
    Respirol Case Rep; 2021 Jun; 9(6):e00759. PubMed ID: 33976888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.
    Taniguchi Y; Horiuchi H; Morikawa T; Usui K
    Case Rep Oncol; 2018; 11(2):323-329. PubMed ID: 29928211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Observational Study of Acquired
    Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
    Front Oncol; 2020; 10():1481. PubMed ID: 33014788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sudden Vision Loss Secondary to Optic Nerve Infiltration as a Presenting Symptom of Metastatic Lung Adenocarcinoma.
    Shamim MM; Whaley M; Rana H; Jeffus SK; Bhatti S; Sallam AB
    Case Rep Ophthalmol Med; 2022; 2022():3614225. PubMed ID: 36404806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Reungwetwattana T; Nakagawa K; Cho BC; Cobo M; Cho EK; Bertolini A; Bohnet S; Zhou C; Lee KH; Nogami N; Okamoto I; Leighl N; Hodge R; McKeown A; Brown AP; Rukazenkov Y; Ramalingam SS; Vansteenkiste J
    J Clin Oncol; 2018 Aug; ():JCO2018783118. PubMed ID: 30153097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib.
    Malapelle U; Ricciuti B; Baglivo S; Pepe F; Pisapia P; Anastasi P; Tazza M; Sidoni A; Liberati AM; Bellezza G; Chiari R; Metro G
    Recent Results Cancer Res; 2018; 211():257-276. PubMed ID: 30069773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
    Saad N; Poudel A; Basnet A; Gajra A
    Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.
    Takeda Y; Naka G; Yamaguchi Y; Hashimoto M; Suzuki M; Izumi S; Sugiyama H
    BMC Cancer; 2020 Oct; 20(1):951. PubMed ID: 33008313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A "triple whammy" in adenocarcinoma lung.
    Patro M; Gothi D; Vaidya S; Sah RB
    Lung India; 2019; 36(4):340-344. PubMed ID: 31290421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.